An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A

Inclusion Criteria:

• Type of subject: Outpatient.

• Informed Consent: A signed and dated written informed consent prior to studyparticipation.

• Age: 40 years of age or older at Visit 1.

• Gender: Male or female subjects.

• Diagnosis: An established clinical history of COPD in accordance with the definitionby the American Thoracic Society/European Respiratory Society [Celli, 2004]

• Smoking History: Current or former cigarette smokers with a history of cigarettesmoking of ≥ 10 pack-years

• Severity of Disease: A post-albuterol/salbutamol FEV1/FVC ratio of <0.70 and apost-albuterol/salbutamol FEV1 of >35% and <70% of predicted normal

• Dyspnea: A score of ≥2 on the Modified Medical Research Council Dyspnea Scale (mMRC)at Visit 1

• Resting Lung Volumes: A resting FRC of ≥120% of predicted normal FRC at Visit 1.

Exclusion Criteria:

• Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnantduring the study.

• Asthma: A current diagnosis of asthma.

• Other Respiratory Disorders: Known respiratory disorders other than COPD including butnot limited to alpha-1 antitrypsin deficiency, active tuberculosis, bronchiectasis,sarcoidosis, lung fibrosis, pulmonary hypertension, and interstitial lung disease.Allergic rhinitis is not exclusionary.

• Other Diseases/Abnormalities: Subjects with historical or current evidence ofclinically significant cardiovascular, neurological, psychiatric, renal, hepatic,immunological, endocrine (including uncontrolled diabetes or thyroid disease) orhaematological abnormalities that are uncontrolled and/or a previous history of cancerin remission for < 5 years prior to Visit 1 (localized carcinoma of the skin that hasbeen resected for cure is not exclusionary). Significant is defined as any diseasethat, in the opinion of the investigator, would put the safety of the subject at riskthrough participation, or which would affect the efficacy or safety analysis if thedisease/condition exacerbated during the study. Any physical or mental abnormalitywhich would affect the patient carrying out exercise tests including peripheralvascular disease should be excluded at the investigators discretion.

• Chest X-Ray: A chest X-ray or computed tomography (CT) scan that reveals evidence ofclinically significant abnormalities not believed to be due to the presence of COPD. Achest X-ray must be taken at Visit 1 if a chest X-ray or CT scan is not availablewithin 6 months prior to Visit 1. For subjects in Germany, if a chest X-ray (or CTscan) is not available in the 6 months prior to Visit 1 the subject will not beeligible for the study.

• Contraindications: A history of allergy or hypersensitivity to anyanticholinergic/muscarinic receptor antagonist, beta2-agonist, lactose/milk protein ormagnesium stearate or a medical condition such as narrow-angle glaucoma, prostatichypertrophy or bladder neck obstruction that, in the opinion of the study physiciancontraindicates study participation or use of an inhaled anticholinergic.

• Hospitalization: Hospitalization for COPD or pneumonia within 12 weeks prior to Visit

• Lung Resection: Subjects with lung volume reduction surgery within the 12 months priorto Screening (Visit 1).

• 12-Lead ECG: An abnormal and significant ECG finding from the 12-lead ECG conducted atVisit 1, including the presence of a paced rhythm on a 12-lead electrocardiogram (ECG)which causes the underlying rhythm and ECG to be obscured. Investigators will beprovided with ECG reviews conducted by a centralized independent cardiologist toassist in evaluation of subject eligibility.

• Screening Labs: Significantly abnormal finding from clinical chemistry and hematologytests at Visit 1.

• Medication Prior to Spirometry: Unable to withhold albuterol/salbutamol for the 4 hourperiod required prior to spirometry testing at each study visit.

• Medications prior to Screening, including depot,oral corticosteroids, combinations ofLABA/ICS, LABA, PDE4 inhibitors.

• Oxygen: Use of long-term oxygen therapy (LTOT) described as oxygen therapy prescribedfor greater than 12 hours a day. As-needed oxygen use (i.e., <12 hours per day) is notexclusionary.

• Nebulized Therapy: Regular use (prescribed for use every day, not for as-needed use)of short-acting bronchodilators (e.g., albuterol/salbutamol) via nebulized therapy

• Pulmonary Rehabilitation Program: Participation in the acute phase of a pulmonaryrehabilitation program within 4 weeks prior to Visit 1. Subjects who are in themaintenance phase of a pulmonary rehabilitation program are not excluded.

• Drug or Alcohol Abuse: A known or suspected history of alcohol or drug abuse within 2years prior to Visit 1.

• Affiliation with Investigator Site: Is an investigator, sub-investigator, studycoordinator, employee of a participating investigator or study site, or immediatefamily member of the aforementioned that is involved in this study